Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Zahra Ramji"'
Autor:
Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Publikováno v:
Liver Cancer (2024)
Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs 12.3 months; HR 0.92, 95% CI 0.79-1.06). The objective response rate (ORR
Externí odkaz:
https://doaj.org/article/d6ae54a6e78a47678e598fa918d4b74a
Autor:
David J Pinato, Kerigo Ndirangu, Richard S Finn, Zahra Ramji, Peter Galle, Catherine Ruth Mitchell, Gabrielle Sophie Redhead
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Increased understanding of how the immune system regulates tumor growth has innovated the use of immunotherapeutics to treat various cancers. The impact of such therapies, including programmed cell death protein 1 (PD-1)/programmed death-l
Externí odkaz:
https://doaj.org/article/98e52ac30ac14b1e9804c53370c436f6
Autor:
Masatoshi Kudo, Richard S. Finn, Masafumi Ikeda, Max W. Sung, Ari D. Baron, Takuji Okusaka, Masahiro Kobayashi, Hiromitsu Kumada, Shuichi Kaneko, Marc Pracht, Tim Meyer, Satoshi Nagao, Kenichi Saito, Kalgi Mody, Zahra Ramji, Leonid Dubrovsky, Josep M. Llovet
Publikováno v:
Liver Cancer (2023)
Background: Treatment with lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh
Externí odkaz:
https://doaj.org/article/9b3dbb00ba7849bcbc864150e49a693b
Autor:
David J Pinato, Peter R Galle, Kerigo Ndirangu, Catherine R Mitchell, Zahra Ramji, Gabrielle Redhead, Richard Finn
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e9b9dc4bc8b44bf3808d9b596c39c829
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Lenvatinib is an approved first-line treatment for unresectable hepatocellular carcinoma (uHCC). We evaluated the safety and efficacy of lenvatinib versus sorafenib in patients with uHCC who deteriorated to Child-Pugh class B (CP-B) on tr
Externí odkaz:
https://doaj.org/article/6b03a8168b334bcbb599080b3ce87926
Autor:
Ruether Dean, Zahra Ramji, Andree Boucher, Chua Neil, Ezzat Shereen, Rondeau Geneviève, Laurie Scott, Hotte Sebastien, Flint Alexander, Wong Ralph, Wendy Hauck, Winquist Eric, Lemieux Bernard, Bouganim Nathaniel, Krzyzanowska monika, Leboeuf Rebecca, Brassard Maryse, Massicotte Marie-Hélène, Mircescu Hortensia, Lamond Nathan, Klimo Paul, Lim Howard
Publikováno v:
Endocrine Abstracts.
Autor:
Masatoshi Kudo, Shukui Qin, Fabio Piscaglia, Arndt Vogel, T.R. Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Richard S. Finn
Publikováno v:
Journal of Clinical Oncology. 40:4078-4078
4078 Background: In REFLECT, lenvatinib was noninferior to sorafenib based on overall survival in pts with uHCC (median 13.6 vs 12.3 mos; hazard ratio [HR] 0.92, 95% CI 0.79–1.06). The objective response rate (ORR) with lenvatinib was 18.8% by blin
Autor:
Zahra Ramji, Mélissa Laflamme
Publikováno v:
The Journal of Foot and Ankle Surgery. 56:648-652
Intra-articular bullet wounds have been found to cause both local and systemic consequences, in particular, when retained over many years. Only a few such cases have been described in published reports, each with different implications, depending on